Rebecca Ellston

3.0k total citations · 1 hit paper
15 papers, 1.5k citations indexed

About

Rebecca Ellston is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Rebecca Ellston has authored 15 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 6 papers in Pulmonary and Respiratory Medicine and 6 papers in Oncology. Recurrent topics in Rebecca Ellston's work include PI3K/AKT/mTOR signaling in cancer (6 papers), Cancer-related Molecular Pathways (4 papers) and Cancer therapeutics and mechanisms (3 papers). Rebecca Ellston is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (6 papers), Cancer-related Molecular Pathways (4 papers) and Cancer therapeutics and mechanisms (3 papers). Rebecca Ellston collaborates with scholars based in United Kingdom, France and Singapore. Rebecca Ellston's co-authors include Trevor Johnson, Victoria Johnson, Nicholas Keen, Andrew Mortlock, Anthony Tighe, Stephen S. Taylor, Stephen Green, Philip J. Jewsbury, Gloria A. Breault and Richard A. Pauptit and has published in prestigious journals such as The Journal of Cell Biology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Rebecca Ellston

15 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores

2003 980 citations Victoria Johnson, Anthony Tighe et al. The Journal of Cell Biology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rebecca Ellston United Kingdom	10	1.1k	940	522	163	137	15	1.5k
Julian M.C. Golec United States	18	1.7k 1.5×	723 0.8×	1.1k 2.1×	73 0.4×	97 0.7×	24	2.3k
Claire Crafter United Kingdom	16	918 0.8×	528 0.6×	650 1.2×	39 0.2×	361 2.6×	26	1.5k
Jürgen Moll Italy	18	702 0.6×	425 0.5×	449 0.9×	24 0.1×	67 0.5×	39	1.2k
Fiona E. Hood United Kingdom	15	1.0k 0.9×	427 0.5×	359 0.7×	61 0.4×	128 0.9×	16	1.3k
Holger Bastians Germany	24	1.5k 1.4×	911 1.0×	679 1.3×	98 0.6×	108 0.8×	47	1.9k
Scott Rosenberg United States	11	1.1k 1.0×	252 0.3×	357 0.7×	106 0.7×	131 1.0×	13	1.3k
Anita Diu‐Hercend United States	8	715 0.6×	583 0.6×	444 0.9×	42 0.3×	41 0.3×	10	1.1k
Francesco Sola Italy	17	780 0.7×	335 0.4×	330 0.6×	26 0.2×	41 0.3×	29	1.0k
Anna Lapuk United States	13	1.0k 0.9×	225 0.2×	433 0.8×	90 0.6×	95 0.7×	17	1.5k
Kwang‐Ai Won United States	6	1.2k 1.0×	384 0.4×	890 1.7×	33 0.2×	186 1.4×	7	1.7k

Countries citing papers authored by Rebecca Ellston

Since Specialization

Citations

This map shows the geographic impact of Rebecca Ellston's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rebecca Ellston with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rebecca Ellston more than expected).

Fields of papers citing papers by Rebecca Ellston

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rebecca Ellston. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rebecca Ellston. The network helps show where Rebecca Ellston may publish in the future.

Co-authorship network of co-authors of Rebecca Ellston

This figure shows the co-authorship network connecting the top 25 collaborators of Rebecca Ellston. A scholar is included among the top collaborators of Rebecca Ellston based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rebecca Ellston. Rebecca Ellston is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Lynch, James T., Urszula M. Polanska, Oona Delpuech, et al.. (2017). Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors. Clinical Cancer Research. 23(24). 7584–7595. 24 indexed citations

Ross, Sarah J., Alexey S. Revenko, Lyndsey Hanson, et al.. (2017). Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS. Science Translational Medicine. 9(394). 143 indexed citations

Barlaam, Bernard, Sabina Cosulich, Sébastien L. Degorce, et al.. (2017). Discovery of a series of 8-(1-phenylpyrrolidin-2-yl)-6-carboxamide-2-morpholino-4H-chromen-4-one as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours. Bioorganic & Medicinal Chemistry Letters. 27(9). 1949–1954. 3 indexed citations

Hudson, Kevin, Urs J. Hancox, Cath Trigwell, et al.. (2016). Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA -Dependent Breast Cancers. Molecular Cancer Therapeutics. 15(5). 877–889. 36 indexed citations

Hudson, Kevin, Urs J. Hancox, Cath Trigwell, et al.. (2015). Abstract 2665: High dose intermittent scheduling of AZD8835, a novel potent and selective inhibitor of PI3Kα and PI3Kδ, identifies potential treatment strategies for PIK3CA-dependent cancers. Cancer Research. 75(15_Supplement). 2665–2665. 1 indexed citations

Barry, Simon T., Elaine Cadogan, Rajesh Odedra, et al.. (2014). Abstract 5409: AZD1152-hQPA Accurins: Nanoparticle formulations showing extended release and the potential for improved therapeutic index. Cancer Research. 74(19_Supplement). 5409–5409. 2 indexed citations

Marques, Rute B., Corrina M.A. de Ridder, Debra Stuurman, et al.. (2014). High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models. European Urology. 67(6). 1177–1185. 82 indexed citations

Davies, Barry R., Andrew Thomason, Rebecca Ellston, et al.. (2014). 457 Preclinical pharmacology of AZD5312, a generation 2.5 antisense oligonucletotide targeting the androgen receptor with differentiated activity from enzalutamide. European Journal of Cancer. 50. 150–150. 3 indexed citations

Cumberbatch, Marie, Ximing Tang, Garry Beran, et al.. (2013). Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma. Clinical Cancer Research. 20(3). 595–603. 22 indexed citations

10.

Hancox, Urs J., Sabina Cosulich, Hannah Dry, et al.. (2013). Abstract 3264: AZD8186: a potent selective inhibitor of PI3Kβ targeting PTEN-deficient tumours dependent on dysregulated PI3Kβ signalling.. Cancer Research. 73(8_Supplement). 3264–3264. 2 indexed citations

11.

Hennequin, Laurent, Peter Ballard, Bénédicte Delouvrié, et al.. (2006). Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: Synthesis and structure–activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 16(10). 2672–2676. 22 indexed citations

12.

Anderson, Malcolm, Gloria A. Breault, J. Breed, et al.. (2003). Imidazo[1,2-a]pyridines: A potent and selective class of cyclin-Dependent kinase inhibitors identified through structure-Based hybridisation. Bioorganic & Medicinal Chemistry Letters. 13(18). 3021–3026. 95 indexed citations

13.

Breault, Gloria A., Rebecca Ellston, Stephen Green, et al.. (2003). Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimisation of substituted 4,6-Bis anilino pyrimidines. Bioorganic & Medicinal Chemistry Letters. 13(18). 2955–2960. 74 indexed citations

14.

Breault, Gloria A., Rebecca Ellston, Stephen Green, et al.. (2003). Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimisation of substituted 2,4-bis anilino pyrimidines. Bioorganic & Medicinal Chemistry Letters. 13(18). 2961–2966. 51 indexed citations

15.

Johnson, Victoria, Anthony Tighe, Rebecca Ellston, et al.. (2003). Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. The Journal of Cell Biology. 161(2). 267–280. 980 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact